Sonoma Pharmaceuticals, INC Form 4 insider transactions

Philippe Weigerstorfer, a Director at Sonoma Pharmaceuticals, Inc., has been granted 10,000 stock options with an exercise price of $1.26.

Amy Trombly, CEO of Sonoma Pharmaceuticals, was granted 10,000 restricted stock units.

John McLaughlin, a Director at Sonoma Pharmaceuticals, Inc., acquired 10,000 stock options with an exercise price of $1.26.

Director Vanessa Jacoby was granted 10,000 stock options in Sonoma Pharmaceuticals, Inc. on July 9, 2026, with a vesting schedule tied to service and potential change of control.

Jerome J. Dvonch, Chief Financial Officer of Sonoma Pharmaceuticals, Inc., was granted 10,000 Restricted Stock Units (RSUs) on July 9, 2026.

John Dal Poggetto, Controller at Sonoma Pharmaceuticals, Inc., reported the acquisition of 7,500 Restricted Stock Units (RSUs) on July 9, 2026.

Sonoma Pharmaceuticals, Inc. director Philippe Weigerstorfer was granted 10,000 stock options with an exercise price of $3.68 as part of the company's annual compensation.

Sonoma Pharmaceuticals, Inc. CEO Amy Moss Trombly received a grant of 10,000 restricted stock units, vesting over three years.

Sonoma Pharmaceuticals' Director John McLaughlin was granted 10,000 stock options with a $3.68 exercise price, vesting over three years.

Sonoma Pharmaceuticals' Chief Financial Officer, Jerome J. Dvonch, was granted 5,000 restricted stock units, vesting on the third anniversary of the grant date or upon a change of control.

Sonoma Pharmaceuticals' Controller, John Dal Poggetto, was granted 5,000 restricted stock units vesting on the third anniversary of the grant date or upon change of control.

Sonoma Pharmaceuticals, Inc. Director Jay E Birnbaum was granted 10,000 stock options with an exercise price of $3.68, vesting over three years, as part of his annual compensation.

Bruce Thornton, Executive VP and COO of Sonoma Pharmaceuticals, Inc., was granted 13,500 Restricted Stock Units as compensation for services performed, vesting on the third anniversary of the grant date or upon change of control.

Sonoma Pharmaceuticals, Inc. Controller John Dal Poggetto was granted 10,000 restricted stock units, vesting over three years or upon a change of control, for services performed.

Sonoma Pharmaceuticals, Inc.'s Chief Financial Officer, Jerome J. Dvonch, was granted 13,500 restricted stock units, increasing his total beneficial ownership of derivative securities to 25,515 units.

Sonoma Pharmaceuticals, Inc. Chief Executive Officer, Amy Moss Trombly, was granted 13,500 restricted stock units as part of her compensation.

Bruce Thornton, Executive VP & COO of Sonoma Pharmaceuticals, reports the acquisition of 10,000 Restricted Stock Units (RSUs) as part of the company's annual equity grant.

Jay E. Birnbaum, a director of Sonoma Pharmaceuticals, acquired stock options exercisable for 7,500 shares of common stock on January 2, 2025.

Director John McLaughlin receives stock options for services performed on the Board of Directors of Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals' CEO, Amy Trombly, received 10,000 restricted stock units (RSUs) as part of the company's annual equity grant.

Philippe Weigerstorfer, a director of Sonoma Pharmaceuticals, acquired 7,500 stock options on January 2, 2025, as part of the company's annual grant for board services.

Jerome Dvonch, CFO of Sonoma Pharmaceuticals, reports the acquisition of 10,000 restricted stock units (RSUs) on January 2, 2025, according to a Form 4 filing with the SEC.

John Dal Poggetto, Controller of Sonoma Pharmaceuticals, reports the acquisition of 7,500 Restricted Stock Units (RSUs) and disposal of 10,250 RSUs on January 2, 2025, according to a Form 4 filing.

Amy Trombly, CEO of Sonoma Pharmaceuticals, was granted 53,586 shares of common stock as part of the company's annual bonus compensation for executives.

Bruce Thornton, Executive Vice President of Sonoma Pharmaceuticals, reports the acquisition of 53,586 shares of common stock as part of an annual bonus and the disposal of 154,411 shares.

Jerome Dvonch, CFO of Sonoma Pharmaceuticals, reports acquiring 53,586 shares and disposing of 84,595 shares of common stock on June 20, 2024.

John Dal Poggetto, Controller of Sonoma Pharmaceuticals, acquired 15,000 shares of common stock as part of his annual bonus compensation.